PNPLA3 and metabolic dysfunction-associated steatohepatitis: The antisense therapeutic ION839/AZD2693from Ionis/AstraZeneca entered phase I trials (Table 3) in 2020 in patients with NASH and fibrosis.168 ION839/AZD2693 targets patatin-like phospholipasedomain-containing 3 (PNPLA3), reducing its expression.151 Mutation of PNPLA3, whichproduces a protein that accumulates on the surface of intracellularlipid droplets, is strongly associated with an increased risk forNASH.169